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Introduction: Chromosomal rearrangements involving neurotrophic 
tyrosine kinase 1 (NTRK1) occur in a subset of non-small cell lung 
cancers (NSCLCs) and other solid tumor malignancies, leading to 
expression of an oncogenic TrkA fusion protein. Entrectinib (RXDX-
101) is an orally available tyrosine kinase inhibitor, including TrkA. 
We sought to determine the frequency of NTRK1 rearrangements in 
NSCLC and to assess the clinical activity of entrectinib.
Methods: We screened 1378 cases of NSCLC using anchored multi-
plex polymerase chain reaction (AMP). A patient with an NTRK1 gene 
rearrangement was enrolled onto a Phase 1 dose escalation study of 
entrectinib in adult patients with locally advanced or metastatic tumors 
(NCT02097810). We assessed safety and response to treatment.
Results: We identiﬁed NTRK1 gene rearrangements at a frequency 
of 0.1% in this cohort. A patient with stage IV lung adenocrcinoma 
with an SQSTM1-NTRK1 fusion transcript expression was treated 
with entrectinib. Entrectinib was well tolerated, with no grade 3–4 
adverse events. Within three weeks of starting on treatment, the 
patient reported resolution of prior dyspnea and pain. Restaging CT 
scans demonstrated a RECIST partial response (PR) and complete 
resolution of all brain metastases. This patient has continued on treat-
ment for over 6 months with an ongoing PR.
Conclusions: Entrectinib demonstrated signiﬁcant anti-tumor activ-
ity in a patient with NSCLC harboring an SQSTM1-NTRK1 gene 
rearrangement, indicating that entrectinib may be an effective ther-
apy for tumors with NTRK gene rearrangements, including those 
with central nervous system metastases.
(J Thorac Oncol. 2015;10: 1670–1674)
INTRODUCTION
Chromosomal rearrangements resulting in expression 
of oncogenic receptor tyrosine kinase fusions occur in a sub-
set of epithelial malignancies and can underlie sensitivity to 
tyrosine kinase inhibitors1. The tropomyosin-related kinase 
(Trk) proteins TrkA, TrkB, and TrkC are receptor tyrosine 
kinases encoded by NTRK1 NTRK2, and NTRK3, respectively, 
that normally function during neuronal development2. NTRK1 
gene rearrangements in NSCLC were ﬁrst described among a 
population of NSCLC patients with adenocarcinoma histology 
and no detectable EGFR or KRAS mutation, or ALK or ROS1 
gene rearrangement3. Among this cohort, NTRK1 rearrange-
ments were detected at a frequency of 3% by fluorescence in 
situ hybridization (FISH). NTRK1 gene rearrangements also 
occur at low frequencies in other solid tumor malignancies, 
including in colorectal carcinoma, intrahepatic cholangiocar-
cinoma, papillary thyroid cancer, spitzoid neoplasms, glioneu-
ronal tumors, and sarcoma4,5. Gene rearrangements involving 
NTRK2 and NTRK3 have also been observed in a variety of 
solid tumor malignancies5. In all cases, the sequenced fusion 
gene product maintains the tyrosine kinase domain, support-
ing the hypothesis that kinase signaling through these fusion 
products promotes cell growth and survival.
Entrectinib is an orally available small molecule inhibitor 
of TrkA, TrkB, TrkC, ROS1 and ALK. In biochemical kinase 
assays, entrectinib inhibits TrkA with an IC50 of 1.7 nM. 
Entrectinib inhibits cell proliferation, TrkA phosphorylation 
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and downstream pathway activation in the KM-12 human 
colorectal cell line which expresses the TPM3-NTRK1 fusion 
product6. In a KM-12 xenograft, entrectinib induces tumor 
regression and durable tumor stabilization6. Similar potency 
is observed in a model of patient-derived cells (PDC) from 
a colorectal cancer patient harboring TPM3-NTRK1 fusion7. 
Entrectinib is currently in clinical development in trials for 
patients with locally advanced or metastatic solid tumor 
malignancies with molecular alterations (phase 1/2a, NCT 
02097810) or gene rearrangements (phase 2, NCT 02568267) 
in NTRK1, NTRK2, NTRK3, ROS1 or ALK.
MATERIALS AND METHODS
AMP-PCR to Identify NTRK1 Gene 
Rearrangements in NSCLC
For detection of fusion transcripts involving NTRK1 
from clinical samples, we implemented AMP, as previously 
described8. The sequencing library targets known fusion exons 
in multiple oncogenes including ALK, ROS1, RET and NTRK1.
fluorescence In Situ Hybridization (fISH)
Cases with suspected NTRK1 gene rearrangements were 
further conﬁrmed using FISH. We used a break-apart FISH 
approach using BAC clones corresponding to the 5’ (RP11-
1047J23) and 3’ (RP11-1038N13) sequences flanking the 
NTRK1 gene labeled by nick translation in green and red, 
respectively. FFPE slides were de-parafﬁnized, treated with 
protease, and co-denatured with FISH probes using a Hybrite 
slide processor (Abbott Molecular), washed, counterstained, 
and cover-slipped FISH slides and analyzed using an Olympus 
BX61 fluorescence microscope equipped with red, green, 
and DAPI ﬁlters. Images were captured and analyzed using 
Cytovision software (Genetix Inc., San Jose, CA).
Phase 1 Clinical Trial of Entrectinib
The Phase 1 dose escalation study of entrectinib in adult 
patients with locally advanced or metastatic tumors is ongoing 
(NCT02097810). Eligibility criteria include locally advanced 
or metastatic solid tumor malignancy with a NTRK1, NTRK2, 
NTRK3, ROS1 or ALK molecular alteration, measurable disease 
according to Response Evaluation Criteria in Solid Tumors 
(RECIST) v1.1, and Eastern Cooperative Oncology Group 
(ECOG) performance status (PS) ≤ 2. Patients with controlled 
asymptomatic central nervous system (CNS) involvement of 
disease are allowed in the absence of anticonvulsant therapy. 
Toxicities are graded using Common Terminology Criteria for 
Adverse Events (CTCAE) v4.0, and responses are measured 
using RECIST v1.1.
RESULTS
Between July 1 2013 and September 15 2015, we per-
formed AMP testing on 1378 NSCLC tumor specimens and 
identiﬁed two with NTRK1 gene rearrangements (0.1%, 95% 
conﬁdence interval 0.01%, 0.5%). One was a TPM3-NTRK1 
rearrangement previously described8. In a second case, 
we identiﬁed a fusion transcript containing sequence from 
SQSTM1 (sequestosome 1) and NTRK1. Primers extending 
from exon 10 of NTRK1 ampliﬁed contiguous sequence that 
mapped to exon 6 of SQSTM1 (Figure 1A–B). The junction of 
the ampliﬁed fusion transcript lay at the exon boundaries, and 
resulted in an in-frame fusion. The predicted fusion gene prod-
uct includes the PB1 dimerization domain of SQSTM19 with 
the tyrosine kinase domain of TrkA (Figure 1C). The NTRK1 
rearrangement was conﬁrmed by FISH (Figure 1D). Of note, 
SQSTM1 has previously been described as a fusion partner 
with ALK in NSCLC and in B-cell lymphoma10,11. Based on 
these results, we hypothesized that the fusion protein in this 
patient’s tumor was expressed and functional.
The patient is a male who was 45 years old when he was 
diagnosed with stage IV lung adenocarcinoma in 2013. He had a 
30 pack year smoking history, and he developed progressive dis-
ease despite four prior lines of therapy, including carboplatin and 
pemetrexed, pembrolizumab, docetaxel, and vinorelbine. At the 
time of enrollment, the patient had an ECOG performance score 
of 2 with baseline chest wall pain, dyspnea at rest, and an oxygen 
requirement of 3L/min by nasal cannula. He had a palpable left 
chest wall mass measuring approximately 5 cm in diameter with 
associated palpable 1 cm satellite nodules extending from the 
mass into the left axilla. Staging head CT demonstrated 15–20 
brain metastases that were asymptomatic and new compared to 
the most recent prior brain MRI from 18 months earlier.
He enrolled in a phase 1 trial with entrectinib at 400 mg/m2 
PO daily. The drug was well tolerated, with possibly related 
adverse events of grade 1 dysguesia, grade 1 paresthesias, and 
grade 2 fatigue that all subsequently resolved. Within three 
weeks of starting treatment, the patient reported resolution of 
pain and dyspnea, and no longer required supplemental oxygen.
Restaging CT scans at 26 days demonstrated RECIST par-
tial response of -47% (Figure 2 A–D). There was resolution of the 
prior right-sided pleural effusion, marked interval re-expansion 
of the left upper and lower lobes, and partial resolution of the 
previous diffuse consolidative opacity in the left lung. There was 
decreased ground glass and septal thickening of the tumor in other 
areas of the left upper lobe, thought to represent improvement 
of lymphangitic spread of disease. There was decreased pleural 
thickening on the left. In the mediastinum, there was signiﬁcant 
interval regression of previous bulky bilateral lymphadenopathy. 
In the abdomen, there was signiﬁcant improvement of previous 
para-aortic lymphadenopathy. There was increased sclerosis of 
previously visualized bone metastases, consistent with treatment 
response. The left-sided chest wall mass was smaller and flatter 
on exam, and the satellite nodules were no longer palpable. The 
radiographic response was conﬁrmed and ongoing in subsequent 
scans. At day 155, restaging scans demonstrated further tumor 
reduction, -77% compared to baseline (Figure 2 E, F). There was 
ongoing improvement of the left lower lobe consolidation and 
ongoing decreased size of mediastinal lymph nodes. The pre-
vious left chest wall mass was no longer palpable or visible on 
scans. He had no new sites of disease involvement.
The patient also had a complete response of all brain 
metastases on entrectinib. Fifteen to 20 baseline brain metas-
tases had been identiﬁed, the largest of which were in the left 
occipital region, the right thalamus, and the left cerebellum. 
These measured up to 1.7 cm in diameter (Figure 3A–C). At 
day 26, a head CT with contrast demonstrated near resolution 
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of these metastases (Figure 3 D–F), and by day 155 the patient 
continued to have a complete response of all brain metastases 
(Figure 3 G–I). To date, the patient has continued on entrec-
tinib for over 6 months with ongoing partial response and cur-
rent duration of response 4.1 months.
DISCUSSION
Trk signaling is normally involved in neuronal devel-
opment, synaptic function and plasticity. Wild-type TrkA, 
TrkB and TrkC, function through ligand-dependent dimeriza-
tion, leading to phosphorylation of tyrosine residues within 
fIGURE 1. SQSTM1-NTRK1 fusion transcripts detected by AMP in a NSCLC. (A) Contiguous reads from amplified transcripts 
mapped to the locations of SQSTM1 on chromosome 5 and NTRK1 on chromosome 1 (red arrowheads). (B) Visualization of 
subset of sequence read pileup showing fusion reads. The y axis represents read coverage. The x axis represents reference bases 
and their respective codons below. Shown in gray are read portions corresponding to the randomly ligated universal adapter end 
with staggered distribution of reads and differing start positions. Shown in blue are read portions corresponding to the anchored 
end targeted with GSP1 and GSP2. The fusion is in-frame with respect to both transcripts. (C) Schematic drawing of gene fusion 
involving SQSTM1 and NTRK1. TM, transmembrane domain. Not drawn to scale. (D) FISH confirmation SQSTM1-NTRK1 rear-
rangement showed individual 3’ (red only) probe signals that represent a region downstream of the NTRK1 gene along with 
normal paired green and red signals that represent non-rearranged alleles. White arrows highlight representative red only signals.
fIGURE 2. Partial response to entrectinib. Horizontal (A) and coronal (B) images of the chest at day -7 (baseline scan), day 26 
(C, D), and day 155 (E, F) on entrectinib.
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the cytoplasmic domain, recruitment of scaffold proteins, and 
activation of downstream signaling (Figure 4A, B). Signaling 
through the mitogen-activated protein kinase (MAPK), phos-
pholipase C-γ (PLC-γ), and phosphatidylinositol 3-kinase 
(PI3K) pathways is thought to mediate cell differentiation 
and survival2. NTRK1 gene rearrangements, which result in 
expression of TrkA fusion proteins, represent one of the new-
est oncogenic drivers in NSCLC. Like gene rearrangements 
fIGURE 3. Complete response of 
brain metastases to entrectinib. (A-C) 
Baseline head CT scan at day -7  
demonstrating metastases (green 
arrows) in the right thalamus (A), left 
occipital lobe (B) and left cerebellum 
(C). (D-I) Restaging head CT scans 




fIGURE 4. Trk signaling. (A) Schematic diagrams 
showing wild-type TrkA, TrkB or TrkC protein, 
top, and showing an oncogenic fusion involving a 
partner gene that contains a dimerization domain 
and the kinase domain of TrkA, TrkB or TrkC, bot-
tom. Of note, the fusion shown here includes the 
transmembrane (TM) domain, though Trk fusion 
proteins that lack the TM domain have also been 
described. (B) In the absence of ligand, left, Trk 
proteins do not dimerize or activate downstream 
signaling pathways. In the presence of ligand (red 
circle), Trk proteins dimerize, leading to downstream 
pathway activation. Double line represents the cell 
membrane. (C) Fusion oncogenes dimerize in a 
ligand-independent manner, leading to constitua-
tive activation and downstream signaling. Proteins 
and their domains are not draw to scale.
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involving other receptor tyrosine kinases such as ALK or ROS1, 
NTRK gene fusions are thought to function through ligand 
independent dimerization and downstream pathway activa-
tion (Figure 4C). In cell lines that lack oncogenic potential 
at baseline, forced expression of either the MPRIP-NTRK1 or 
CD74-NTRK1 gene fusion results in phosphorylation of TrkA, 
anchorage independent growth, and tumor formation in nude 
mice3. Pharmacologic inhibition of TrkA signaling in cell 
lines expressing constituatively active TrkA causes decreases 
cell viability in vitro3,4,7,12. It has therefore been hypothesized 
that NTRK1 gene rearrangements in NSCLC drive tumor pro-
gression and may confer sensitivity to TrkA inhibition.
In a patient with NTRK1-rearranged NSCLC, treatment 
with entrectinib led to rapid and clinically signiﬁcant improve-
ment of disease with minimal side effects. Notably, all of the 
patient’s CNS metastases, which were discovered on screen-
ing and were not treated with radiation, completely resolved 
on entrectinib, indicating potent CNS penetration and activ-
ity of the drug. This response indicates that, like ALK and 
ROS1 rearrangements in NSCLC, TrkA fusions in NSCLC 
drive tumor growth and survival and are targetable. A recent 
case report describes a similar signiﬁcant clinical response 
to Loxo-101, a small molecule pan-Trk inhibitor, in a patient 
with metastatic sarcoma harboring an LMNA-NTRK1 gene 
rearrangement4, further supporting the hypothesis that NTRK 
gene rearrangements can act as potent oncogenic drivers in 
multiple tumor histologies. We conclude that entrectinib may 
be an effective anti-tumor therapy for patients with NTRK1 
gene rearrangements, including patients with metastatic CNS 
disease.
NTRK1 gene rearrangements in NSCLC are rare. Our 
identiﬁcation of NTRK1 gene rearrangements in 0.1% of 
NSCLCs in this cohort is lower than the frequency of up to 
3%, as described previously3. Consistent with our ﬁndings, 
however, is the observation that no NTRK1 fusion transcripts 
were detected by RT-PCR among a cohort of 268 Japanese 
NSCLC surgical resection cases12. Furthermore, the AMP 
assay has demonstrated 100% sensitivity (95% conﬁdence 
limit 99.3–100%) compared to FISH for detection of gene 
rearrangements involving ALK, ROS1 and RET8. The incon-
sistency between our results and those previously published3 
may be partially explained by the fact that Vaishnavi and col-
leagues focused on a cohort of patients that had previously 
screened negative for other gene alterations by standard 
clinical testing, whereas our cohort was largely previously 
unscreened. Furthermore, FISH may detect chromosomal 
rearrangements that do not result in expression of a fusion 
transcript, or in which a fusion transcript is expressed at 
low levels, whereas AMP detects the fusion RNA transcript. 
Finally, we note that our cohort includes a mix of metastatic 
and early-stage NSCLCs. It is possible that NTRK1 rear-
rangements may be more common in metastatic disease, 
as may be the case for ALK rearrangements13. Given the 
low frequency of NTRK1 gene rearrangements, screening 
using FISH may not be practical due to limitations of tis-
sue availability or cost. Incorporation of NTRK1 rearrange-
ment testing into a multiplexed NGS based assay, as we 
have done using AMP, allows for simultaneous screening 
for NTRK1 gene rearrangements among other more com-
mon gene rearrangements8. The profound and durable clini-
cal response of a patient with NTRK1-rearranged NSCLC to 
entrectinib argues strongly for screening patients with both 
NSCLC and other solid tumor malignancies for NTRK gene 
rearrangements.
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